Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice

Full text
Author(s):
Show less -
Gentil, Fernanda [1] ; Bargieri, Daniel Y. [2] ; Leite, Juliana A. [3] ; Francoso, Katia S. [1] ; Patricio, Mariana B. M. [1] ; Espindola, Noeli M. [1] ; Vaz, Adelaide J. [1] ; Palatnik-de-Sousa, Clarisa B. [4] ; Rodrigues, Mauricio M. [2] ; Costa, Fabio T. M. [3] ; Soares, Irene S. [1]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo - Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 Sao Paulo - Brazil
[3] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, BR-13083862 Campinas, SP - Brazil
[4] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio De Janeiro - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Vaccine; v. 28, n. 38, p. 6183-6190, AUG 31 2010.
Web of Science Citations: 26
Abstract

The Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development of a malaria vaccine against asexual stages of Plasmodium. We recently identified domain II (DII) of Plasmodium vivax AMA-1 (PvAMA-1) as a highly immunogenic region recognised by IgG antibodies present in many individuals during patent infection with P. vivax. The present study was designed to evaluate the immunogenic properties of a bacterial recombinant protein containing PvAMA-1 DII. To accomplish this, the recombinant protein was administered to mice in the presence of each of the following six adjuvants: Complete/Incomplete Freund's Adjuvant (CFA/IFA), aluminium hydroxide (Alum), Quil A, QS21 saponin, CpG-ODN 1826 and TiterMax. We found that recombinant DII was highly immunogenic in BALB/c mice when administered in the presence of any of the tested adjuvants. Importantly, we show that DII-specific antibodies recognised the native AMA-1 protein expressed on the surface of P. vivax merozoites isolated from the blood of infected patients. These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria. (C) 2010 Elsevier Ltd. All rights reserved. (AU)